How to Play NVO Stock After New Drug’s Success in Obesity Study
Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage study of its investigational candidate, amycretin, in overweight/obese patients. The study met its primary safety endpoint as amycretin demonstrated a safety profile consistent with incretin-based therapies. Superior dose-dependent weight loss was also observed upon treatment with the […]
How to Play the Stock
Novo Nordisk NVO shares have lost 25.1% in the past three months compared with the industry’s decline of 17.7%. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below. The stock is currently trading below both its 50 and 200-day moving averages. Zacks Investment […]